Citadel Advisors
ALXN

Citadel Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Citadel Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,248,848
Closed -$597M – 15334
2021
Q2 		$597M Buy
3,248,848
+745,676
+30% +$128M 0.13% 74
2021
Q1 		$383M Buy
2,503,172
+1,675,222
+202% +$259M 0.09% 132
2020
Q4 		$129M Buy
827,950
+286,243
+53% +$36.8M 0.03% 426
2020
Q3 		$62M Sell
541,707
-587,984
-52% -$63.4M 0.02% 722
2020
Q2 		$127M Sell
1,129,691
-1,746,572
-61% -$185M 0.05% 317
2020
Q1 		$258M Buy
2,876,263
+2,806,057
+3,997% +$275M 0.12% 96
2019
Q4 		$7.59M Sell
70,206
-16,889
-19% -$1.81M ﹤0.01% 2534
2019
Q3 		$8.53M Sell
87,095
-117,979
-58% -$13.3M ﹤0.01% 2412
2019
Q2 		$26.9M Buy
205,074
+134,585
+191% +$17.3M 0.01% 1155
2019
Q1 		$9.53M Sell
70,489
-372,439
-84% -$46.3M ﹤0.01% 2143
2018
Q4 		$43.1M Sell
442,928
-907,169
-67% -$107M 0.02% 698
2018
Q3 		$188M Sell
1,350,097
-378,393
-22% -$47.5M 0.08% 188
2018
Q2 		$215M Buy
1,728,490
+1,034,537
+149% +$121M 0.11% 138
2018
Q1 		$77.3M Sell
693,953
-1,292,263
-65% -$154M 0.04% 409
2017
Q4 		$238M Buy
1,986,216
+1,254,689
+172% +$153M 0.14% 109
2017
Q3 		$103M Sell
731,527
-385,221
-34% -$52.3M 0.08% 247
2017
Q2 		$136M Buy
1,116,748
+1,012,751
+974% +$118M 0.12% 151
2017
Q1 		$12.6M Buy
103,997
+78,149
+302% +$10.1M 0.01% 1269
2016
Q4 		$3.16M Sell
25,848
-191,481
-88% -$23.4M ﹤0.01% 2437
2016
Q3 		$26.6M Sell
217,329
-1,186,651
-85% -$153M 0.03% 704
2016
Q2 		$164M Buy
1,403,980
+1,349,404
+2,473% +$191M 0.18% 65
2016
Q1 		$7.6M Buy
54,576
+45,839
+525% +$6.73M 0.01% 1411
2015
Q4 		$1.67M Sell
8,737
-64,096
-88% -$11.2M ﹤0.01% 2953
2015
Q3 		$11.4M Sell
72,833
-342,262
-82% -$62.4M 0.01% 1257
2015
Q2 		$75M Sell
415,095
-726,759
-64% -$125M 0.07% 326
2015
Q1 		$198M Buy
1,141,854
+892,456
+358% +$162M 0.19% 79
2014
Q4 		$46.1M Sell
249,398
-51,159
-17% -$9.48M 0.05% 509
2014
Q3 		$49.8M Sell
300,557
-249,310
-45% -$40.9M 0.05% 416
2014
Q2 		$85.9M Buy
549,867
+103,142
+23% +$16.3M 0.1% 200
2014
Q1 		$68M Buy
446,725
+206,800
+86% +$32.9M 0.08% 272
2013
Q4 		$31.9M Sell
239,925
-1,268,531
-84% -$152M 0.04% 557
2013
Q3 		$175M Buy
1,508,456
+545,684
+57% +$59.9M 0.27% 48
2013
Q2 		$88.8M Buy
+962,772
New +$92.8M 0.15% 121

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ALXN Position: Q3 2021 in Review

Citadel Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,248,848 shares — an estimated $597M sold.

Citadel Advisors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $597M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Citadel Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Citadel Advisors sold 3,248,848 Alexion Pharmaceuticals shares in Q3 2021, an estimated $597M.
  • Citadel Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Citadel Advisors's Alexion Pharmaceuticals position peaked at $597M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.